| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/02/2009 | WO2009039959A1 Use of peptide wmnstgftkvcgappc as a therapeutic agent |
| 04/02/2009 | WO2009039958A1 Therapeutic uses of peptides ysaypdsvpmms and wmnstgftkvcgappc |
| 04/02/2009 | WO2009039957A2 Use of angiotensin ii as a therapeutic agent in the treatment of eg s. pneumoniae infection |
| 04/02/2009 | WO2009039773A1 New medicine use of 1-substituted aryl -2(1h)-pyridone |
| 04/02/2009 | WO2009039731A1 Preparation of 5,6-dimethylxanthone-4-acetic acid, the derivatives prepared and pharmaceutical formulations thereof |
| 04/02/2009 | WO2009039584A1 Diagnosis and treatment of diseased and damaged tissue |
| 04/02/2009 | WO2009039553A1 Benzothiazole compounds |
| 04/02/2009 | WO2009023269A3 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5h-pyrimido [4, 5-b[1, 4] diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases |
| 04/02/2009 | WO2009020905A3 Ultraconserved regions encoding ncrnas |
| 04/02/2009 | WO2009011880A3 Heterocyclic modulators of pkb |
| 04/02/2009 | WO2009010299A8 Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| 04/02/2009 | WO2009005809A3 Compositions and methods for treating and diagnosing cancer |
| 04/02/2009 | WO2008150485A3 Erbb2 binding proteins and use thereof |
| 04/02/2009 | WO2008141282A3 Materials and methods for foxp3 tumor suppression |
| 04/02/2009 | WO2008110777A3 Modulators of vegf splicing as pro- and anti-angiogenic agents |
| 04/02/2009 | WO2008000517A3 Conjugates for innate immunotherapy of cancer |
| 04/02/2009 | US20090088573 Biologically active peptides and compositions, their use |
| 04/02/2009 | US20090088558 Tumor necrosis factor specific antibody hybrid for use in treatment and prevention of autoimmune, rheumatoid arthritic, graft rejection and graft-versus-host disorder |
| 04/02/2009 | US20090088478 Novel compounds as histone deacetylase inhibitors |
| 04/02/2009 | US20090088438 NEW TYROSINE DERIVATIVES AS PPARy MODULATORS |
| 04/02/2009 | US20090088436 P38 Kinase Inhibiting Agents |
| 04/02/2009 | US20090088429 Isoquinoline Derivatives |
| 04/02/2009 | US20090088412 withanolide compounds extracted from a Solanaceae plant as anticancer agents; solvent extraction from Tubocapsicum anomalum |
| 04/02/2009 | US20090088410 Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| 04/02/2009 | US20090088407 Compounds, methods and pharmaceutical compositions for inhibiting parp |
| 04/02/2009 | US20090088404 Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| 04/02/2009 | US20090088402 Novel agent for inducing apoptosis comprising msx1 or a gene encoding the same as an active ingredient |
| 04/02/2009 | US20090088401 In-situ cancer autovaccination with intratumoral stabilized dsRNA viral mimic |
| 04/02/2009 | US20090088398 Recombinant adenoviral vectors and methods of use |
| 04/02/2009 | US20090088392 Treatment of melanoma |
| 04/02/2009 | US20090088385 immunoglobulins; fibronectins; drug screening |
| 04/02/2009 | US20090088382 Use of the cathelicidin LL-37 and derivatives therof for wound healing |
| 04/02/2009 | US20090088376 Dendrimer based compositions and methods of using the same |
| 04/02/2009 | US20090088375 Human prolactin antagonist-angiogenesis inhibitor fusion proteins |
| 04/02/2009 | US20090088368 Compositions comprising them as ppar modulators |
| 04/02/2009 | US20090087489 Imatinib compositions |
| 04/02/2009 | US20090087482 Temperature-Sensitive Liposomal Formulation |
| 04/02/2009 | US20090087474 Therapeutic use of growth factors,nsg29 and nsg31 |
| 04/02/2009 | US20090087450 Combination therapy of hybrid cells with BCG injection for treating Cancer Patients |
| 04/02/2009 | US20090087442 antibody designated RM4 and selectively binds to an antigen designated AgRM4; for treament of neoplasia; competitive binding; kits |
| 04/02/2009 | US20090087441 treating lung cancer with PI-3 kinase inhibitor acetic acid 4-diallylaminomethylene-6-hydroxy-1- alpha -methoxymeth-yl-10 beta ,13 beta -dimethyl-3,7,17-trioxo-1,3,4,7,10,11 beta ,12,13,14 alpha ,15,16,17-dodecahydro-2-oxa-cyclopenta [ alpha ]phenanthren-11-yl ester |
| 04/02/2009 | US20090087440 Methods for Treating Cancer |
| 04/02/2009 | US20090087437 Methods and compositions relating to the regulation of apoptosis by muc1 and bh3-containing proapoptotic proteins |
| 04/02/2009 | US20090087432 TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES |
| 04/02/2009 | US20090087423 Novel protein complex and use thereof |
| 04/02/2009 | US20090087404 Methods of treating cancer using il-21 and monoclonal antibody therapy |
| 04/02/2009 | DE102008013016A1 Verbindungen aus Myrothecium Sp. zur Hemmung des Krebszellwachstums Compounds from Myrothecium Sp. To inhibit cancer cell growth |
| 04/02/2009 | DE102007044094A1 Herstellung von Blattextrakten von Pittosporum phillyraeoides und deren Verwendung in der Medizin Preparation of leaf extracts of Pittosporum phillyraeoides and their use in medicine |
| 04/02/2009 | DE102007032507A1 Pyridazinonderivate Pyridazinone derivatives |
| 04/02/2009 | CA2704711A1 Thiazolopyrimidine p13k inhibitor compounds and methods of use |
| 04/02/2009 | CA2700986A1 Anti-glypican-3 antibody having improved kinetics in plasma |
| 04/02/2009 | CA2700985A1 Pharmaceutical compositions containing the enzyme cyprosin, an aspartic peptidase from cynara cardunculus and its inclusion in antitumour formulations |
| 04/02/2009 | CA2700979A1 Pyrimidine derivatives as protein kinase inhibitors |
| 04/02/2009 | CA2700844A1 Stable imatinib compositions |
| 04/02/2009 | CA2700810A1 Immunoliposomes for treatment of cancer |
| 04/02/2009 | CA2700723A1 Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| 04/02/2009 | CA2700673A1 Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors |
| 04/02/2009 | CA2700665A1 Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2] |
| 04/02/2009 | CA2700664A1 Therapies for treating cancer using combinations of cox-2 inhibitors and aromatase inhibitors or combinations of cox-2 inhibitors and estrogen receptor antagonists |
| 04/02/2009 | CA2700365A1 Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis |
| 04/02/2009 | CA2700274A1 Quinone derivatives, pharmaceutical compositions, and uses thereof |
| 04/02/2009 | CA2700267A1 Azacytidine analogues and uses thereof |
| 04/02/2009 | CA2700088A1 Quinolone derivative |
| 04/02/2009 | CA2699244A1 Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent |
| 04/02/2009 | CA2699241A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699177A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699170A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699154A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699153A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699100A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699077A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699073A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699069A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699068A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699065A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699055A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699054A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699052A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699049A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699047A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699039A1 Use of bpp-b as a therapeutic agent |
| 04/02/2009 | CA2699035A1 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent |
| 04/02/2009 | CA2699000A1 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-arg-gly-asp-asn-pro-oh as a therapeutic agent |
| 04/02/2009 | CA2698775A1 Big gastrin i as a therapeutic agent |
| 04/02/2009 | CA2698772A1 Proadrenomedullin alone or in combination with big gastrin i as a therapeutic agent |
| 04/02/2009 | CA2698768A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698764A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698762A1 Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
| 04/02/2009 | CA2698751A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698673A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698672A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2698609A1 Novel antibodies |
| 04/01/2009 | EP2042598A1 5T4 tumour-associated antigen for use in tumour immunotherapy |
| 04/01/2009 | EP2042596A1 Polypeptides involved in immune response |
| 04/01/2009 | EP2042513A1 Galectin 9-polymer conjugate |
| 04/01/2009 | EP2042510A2 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleid acid (siNA) |
| 04/01/2009 | EP2042509A1 Modulators of the function of FAS receptors and other proteins |
| 04/01/2009 | EP2042503A1 Compound having acidic group which may be protected, and use thereof |
| 04/01/2009 | EP2042500A1 N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-urea compounds, pharmaceutical compositions comprising them, their preparation and their use as Tie2-kinase inhibitors |
| 04/01/2009 | EP2042196A2 Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |